Compare
Aspira Women's Health Inc. vs Insight Molecular Diagnostics Inc. vs Immucell Corp vs Alpha Teknova, Inc.
| Latest fiscal year | Aspira Women's Health Inc. AWHL | Insight Molecular Diagnostics Inc. IMDX | Immucell Corp ICCC | Alpha Teknova, Inc. TKNO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.22M | $4.05M | $27.64M | $40.52M |
| Revenue growth (YoY) | +0.4% | +115.6% | +4.3% | +7.4% |
| Gross margin | 64.2% | 56.7% | 41.4% | 33.2% |
| Operating margin | -85.9% | n/m | 6.0% | -41.9% |
| Net margin | -138.7% | n/m | -3.8% | -42.6% |
| Net income | -$12.78M | -$50.22M | -$1.04M | -$17.26M |
| EPS (Diluted) | -$0.37 | -$1.65 | -$0.12 | -$0.32 |
| Operating cash flow | -$7.03M | -$22.18M | $2.48M | -$8.65M |
| Free cash flow | -$7.04M | -$25.37M | $1.22M | -$9.79M |
| Cash & equivalents | $1.75M | $11.58M | $3.81M | $5.91M |
| Total assets | $5.46M | $25.76M | $42.53M | $103.58M |
| Total liabilities | $12.39M | $57.22M | $15.48M | $34.81M |
| Shareholders' equity | -$6.93M | -$31.46M | $27.06M | $68.78M |
| Return on year-end equity | n/a | n/a | -3.8% | -25.1% |
| Shares outstanding | 43.48M | 28.68M | 9.05M | 53.56M |
Revenue, most recent five fiscal years
| Fiscal year | Aspira Women's Health Inc. | Insight Molecular Diagnostics Inc. | Immucell Corp | Alpha Teknova, Inc. |
|---|---|---|---|---|
| Latest | $9.22M Ended 2025-12-31 | $4.05M Ended 2025-12-31 | $27.64M Ended 2025-12-31 | $40.52M Ended 2025-12-31 |
| 1 year earlier | $9.18M Ended 2024-12-31 | $1.88M Ended 2024-12-31 | $26.49M Ended 2024-12-31 | $37.74M Ended 2024-12-31 |
| 2 years earlier | $9.15M Ended 2023-12-31 | $1.50M Ended 2023-12-31 | $17.47M Ended 2023-12-31 | $36.68M Ended 2023-12-31 |
| 3 years earlier | n/a | $958.0K Ended 2022-12-31 | $18.57M Ended 2022-12-31 | $41.42M Ended 2022-12-31 |
| 4 years earlier | n/a | $2.20M Ended 2021-12-31 | $19.24M Ended 2021-12-31 | $36.89M Ended 2021-12-31 |